Elevating care in Hidradenitis Suppurativa; a
doctor and nurse perspective
Tuesday 27th February 2024
6:30PM – 7:30PM GMT
This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited, and is for UK Healthcare Professionals only.
We look forward to your presence at the upcoming Novartis dermatology webinar: ‘Elevating care in Hidradenitis Suppurativa; a doctor and nurse perspective’. This webinar will be the first of three this year that Novartis aim to provide information and education across HS and Psoriasis.
Our first webinar will focus on the burden of HS to patients and the NHS and what does a typical patient journey look like from diagnosis through to treatment. Will we also explore the view nationally of treating this disease and share tips to further facilitate better outcomes for patients.
Teena Mackenzie – Inflammatory disease & Biologics Advanced Nurse Practitioner, Royal Berkshire NHS Foundation Trust, BDNG Education and Development Lead.
Teena has a keen interest in inflammatory Skin diseases and has developed her role to specialise in Psoriasis, Eczema and Biologics. Teena is principal investigator for BADBIR and sits on the executive steering committee. She has worked on a variety of global, academic, clinical studies. Teena is presently undertaking a MSc in psychology, mental health and wellbeing and is Involved in the psycho dermatology service committee. Teena leads education and development for the BDNG nationally.
Emmanuel Toni, Advanced Nurse Practitioner in Inflammatory Skin Disease, St St John’s Institute of Dermatology, Guy’s Hospital
Emmanuel is an advanced nurse practitioner in dermatology. His area of special interest is medical dermatology. He is currently completing a PhD at the UWE Bristol exploring the use of social media as a tool to educate the public around skin disease and reduce stigma amongst non-sufferers. He also has published a children’s book called the Little Knight with Psoriasis and is hoping to publish further books with an aim of reducing stigma and increasing awareness for those with skin issues.
Dr Ellie Rashid – Consultant Dermatologist at Guy’s and St Thomas’ NHS Foundation Trust
Ellie Rashid is a consultant dermatologist at Guy’s and St Thomas’ NHS Foundation Trust. She is clinical lead for the complex tertiary hidradenitis suppurativa (HS) service and runs the HS clinical trials service.
Ellie is an honorary senior clinical lecturer at King’s College London and is interested in translational clinical research. She spent 3 years as a research fellow studying mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa (RDEB) and was awarded a PhD in stem cells and regenerative medicine.
Cosentyx (secukinumab) indications in Dermatology:
Adult plaque psoriasis
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Paediatric plaque psoriasis
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.
Hidradenitis suppurativa (HS)
Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.
Prescribing information and adverse event reporting for Cosentyx (secukinumab) can be found here.
Cosentyx (secukinumab) Summary of Product Characteristics
This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited, and is for UK Healthcare Professionals only. Novartis products will be discussed in this meeting.
Adverse Event Reporting:
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ Adverse events should also be reported to Novartis via email@example.com or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report. If you have a question about the product, please contact Medical Information on 01276 698370 or by email at firstname.lastname@example.org.
© 2024 Novartis Pharmaceuticals UK Ltd
407934 | February 2024